Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications
Obesity · 2026-06 · 34 (6) · 1331-1342
DOI: 10.1002/oby.70208 ↗At a glance
Vergleichsstudie in Obesity, published online on 2026-05-12. Written by Kristina H Lewis and 10 co-authors. Institution: Department of Epidemiology & Prevention, Department of Implementation Science, Division of Public Health Sciences, Wake Forest University Health Scie…. Major MEDLINE topics: Obesity, Health Care Costs, Anti-Obesity Agents. 39 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (original language)
Objective
This study compared changes in health care costs and use across cohorts initiating four obesity medications (OMs).
Methods
Commercial insurance claims were used to identify new initiators of phentermine ( n = 136,788), phentermine‐topiramate‐ER ( n = 13,888), naltrexone‐bupropion‐SR ( n = 28,712), or liraglutide ( n = 49,266) for obesity. Multivariable difference‐in‐differences analyses compared the three newer drugs to phentermine for change in total annual prescription drug and health care costs, outpatient visits, and acute care use (combined emergency department visits and hospital stays).
Results
Up to 3 years after OM initiation, prescription and total health care costs were higher for all three newer OM cohorts relative to phentermine, with liraglutide having the greatest comparative increase in annual costs (e.g., total costs 73.6% [70.9%, 76.3%] higher in year 1). Primary care physician visit frequency was slightly lower for the newer OMs (e.g., −12.6% [−13.6%, −11.6%] in year 1 for liraglutide).
Conclusions
The cost of OM treatment, even for medications that preceded highly effective weekly incretin analogues, appeared to increase overall prescription spending and total health care costs. Yet, other than a relative decrease in primary care physician visit frequency, more costly OMs were not associated with favorable changes in health care use patterns compared to generic phentermine. Reductions in OM cost and other interventions to support their longer‐term use may be needed to fully realize the promise of these medications.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Epidemiology & Prevention, Department of Implementation Science, Division of Public Health Sciences, Wake Forest University Health Sciences, Winston-Salem, North Carolina, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
- Department of Medicine, Duke University, Durham, North Carolina, USA.
- Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina, USA.
- Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
ORCID profiles: Kristina H Lewis, David E Arterburn
Funding
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Cite
APA
Lewis, K. H., Zhang, F., LeCates, R. F., Argetsinger, S., Albert, S., Iyer, G. S., Connolly, J. G., Wharam, J. F., Arterburn, D. E., Ross-Degnan, D., & Toh, S. (2026). Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications. Obesity, 34(6), 1331-1342. https://doi.org/10.1002/oby.70208
Vancouver
Lewis KH, Zhang F, LeCates RF, Argetsinger S, Albert S, Iyer GS, et al. Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications. Obesity. 2026;34(6):1331-1342. doi:10.1002/oby.70208
BibTeX
@article{Lewis2026,
author = {Lewis, Kristina H and Zhang, Fang and LeCates, Robert F and Argetsinger, Stephanie and Albert, Stefanie and Iyer, Geetha S and Connolly, John G and Wharam, James F and Arterburn, David E and Ross-Degnan, Dennis and Toh, Sengwee},
title = {Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications},
journal = {Obesity},
year = {2026},
volume = {34},
number = {6},
pages = {1331--1342},
doi = {10.1002/oby.70208}
}
EUVIMED